OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory tract (Broncho-Vaxom®) and urinary tract (Uro-Vaxom®) infections, also active in the treatment of vascular diseases. Its Swiss affiliate, OM Pharma Suisse SA is based in Villars-sur-Glâne (Canton Fribourg) and owns also a strong foothold in CNS related diseases with its key brands Symfona® and Trittico®.

Outside of Switzerland, OM Pharma operates mainly through a strong network of international partners and invests its entire profit in research and development. Several ongoing clinical trials for Broncho-Vaxom® and Symfona® are conducted in Switzerland.